Borrow it
Coverart for item
The Resource Drugs, money, and secret handshakes : the unstoppable growth of prescription drug prices, Robin Feldman, University of California Hastings College of the Law

Drugs, money, and secret handshakes : the unstoppable growth of prescription drug prices, Robin Feldman, University of California Hastings College of the Law

Creator
Author
Summary
  • "In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills"--
  • "Everyone has a limit. Every budget has an end point. Although sellers would love to raise prices continually, it does not take fancy economics to know that at some point, the money runs out. Why isn't that basic principle working as expected in the pharmaceutical industry? Instead, drug prices are rising continually and reaching astronomical levels, with no end in sight. In May of 2018, analysts reported that a company is contemplating a $1.5 million price tag for its new hemophilia cure. (The current hemophilia therapies already cost an astounding $580,000 to $800,000 per year. ) Along the same lines, Spark therapeutics' cure for a rare form of blindness will cost $850,000, rivaling Novartis' planned $475,000 price tag for its Car-T drug Kymriah. Even outside the eye-popping headlines, prescription drug prices across the board have risen to an alarming and puzzling level. A government inspector general's report found that the high cost of brand medications for common conditions (diabetes, high cholesterol, and asthma) were the true problem for patients on Medicare. In fact, pharmaceutical companies have raised the prices most sharply for commonly used medications such as these. Similarly, an analyst report concluded that in 2016, the average price for a set of specialty drugs known as "orphan drugs" was $140,000 a year and the average price of ordinary drugs was almost $28,000 a year. The list price of drugs tells only part of the story, given the many rebate and discount processes that exist within the industry. Nevertheless, real spending for drugs is rising as well"--
Language
eng
Work
Publication
Extent
xiv, 186 pages
Contents
  • 1. Introduction; 2. The landscape
  • where do the dollars flow; 3. PBMs and insurers; 4. Pharmacies, doctors, and patient groups; 5. May your drug price be ever green; 6. Solutions
Isbn
9781108482455
Instance
Label
Drugs, money, and secret handshakes : the unstoppable growth of prescription drug prices
Title
Drugs, money, and secret handshakes
Title remainder
the unstoppable growth of prescription drug prices
Statement of responsibility
Robin Feldman, University of California Hastings College of the Law
Creator
Author
Subject
Language
eng
Summary
  • "In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills"--
  • "Everyone has a limit. Every budget has an end point. Although sellers would love to raise prices continually, it does not take fancy economics to know that at some point, the money runs out. Why isn't that basic principle working as expected in the pharmaceutical industry? Instead, drug prices are rising continually and reaching astronomical levels, with no end in sight. In May of 2018, analysts reported that a company is contemplating a $1.5 million price tag for its new hemophilia cure. (The current hemophilia therapies already cost an astounding $580,000 to $800,000 per year. ) Along the same lines, Spark therapeutics' cure for a rare form of blindness will cost $850,000, rivaling Novartis' planned $475,000 price tag for its Car-T drug Kymriah. Even outside the eye-popping headlines, prescription drug prices across the board have risen to an alarming and puzzling level. A government inspector general's report found that the high cost of brand medications for common conditions (diabetes, high cholesterol, and asthma) were the true problem for patients on Medicare. In fact, pharmaceutical companies have raised the prices most sharply for commonly used medications such as these. Similarly, an analyst report concluded that in 2016, the average price for a set of specialty drugs known as "orphan drugs" was $140,000 a year and the average price of ordinary drugs was almost $28,000 a year. The list price of drugs tells only part of the story, given the many rebate and discount processes that exist within the industry. Nevertheless, real spending for drugs is rising as well"--
Assigning source
  • Provided by publisher
  • Provided by publisher
Cataloging source
DLC
http://library.link/vocab/creatorName
Feldman, Robin
Dewey number
338.4/76151
Illustrations
illustrations
Index
index present
LC call number
RS100
LC item number
.F45 2019
Literary form
non fiction
Nature of contents
bibliography
NLM call number
QV 736
http://library.link/vocab/subjectName
  • Pharmaceutical industry
  • Drugs
  • Pharmaceutical policy
Label
Drugs, money, and secret handshakes : the unstoppable growth of prescription drug prices, Robin Feldman, University of California Hastings College of the Law
Instantiates
Publication
Copyright
Bar code
  • 31223134252692
  • 31223134252684
Bibliography note
Includes bibliographical references and index
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
1. Introduction; 2. The landscape -- where do the dollars flow; 3. PBMs and insurers; 4. Pharmacies, doctors, and patient groups; 5. May your drug price be ever green; 6. Solutions
Dimensions
24 cm
Extent
xiv, 186 pages
Isbn
9781108482455
Lccn
2018049432
Media category
unmediated
Media MARC source
rdamedia
Media type code
  • n
Other physical details
illustrations
System control number
(OCoLC)1076550226
Label
Drugs, money, and secret handshakes : the unstoppable growth of prescription drug prices, Robin Feldman, University of California Hastings College of the Law
Publication
Copyright
Bar code
  • 31223134252692
  • 31223134252684
Bibliography note
Includes bibliographical references and index
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
1. Introduction; 2. The landscape -- where do the dollars flow; 3. PBMs and insurers; 4. Pharmacies, doctors, and patient groups; 5. May your drug price be ever green; 6. Solutions
Dimensions
24 cm
Extent
xiv, 186 pages
Isbn
9781108482455
Lccn
2018049432
Media category
unmediated
Media MARC source
rdamedia
Media type code
  • n
Other physical details
illustrations
System control number
(OCoLC)1076550226

Subject

Library Locations

    • Marina LibraryBorrow it
      1890 Chestnut Street, San Francisco, CA, 94123, US
      37.801325 -122.434154
    • San Francisco Public LibraryBorrow it
      100 Larkin Street, San Francisco, CA, 94102, US
      37.779376 -122.415795

Library Links

Structured data from the Bibframe namespace is licensed under the Creative Commons Attribution 4.0 International License by San Francisco Public Library. Additional terms may apply to data associated with third party namespaces.